Lu, J., Hu, D., Zhang, Y., Ma, C., Shen, L., & Shuai, B. (2023). Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Frontiers in Oncology, 13, . https://doi.org/10.3389/fonc.2023.1133828
Chicago Style (17th ed.) CitationLu, Junjie, Desheng Hu, Yan Zhang, Chen Ma, Lin Shen, and Bo Shuai. "Current Comprehensive Understanding of Denosumab (the RANKL Neutralizing Antibody) in the Treatment of Bone Metastasis of Malignant Tumors, Including Pharmacological Mechanism and Clinical Trials." Frontiers in Oncology 13 (2023). https://doi.org/10.3389/fonc.2023.1133828.
MLA (9th ed.) CitationLu, Junjie, et al. "Current Comprehensive Understanding of Denosumab (the RANKL Neutralizing Antibody) in the Treatment of Bone Metastasis of Malignant Tumors, Including Pharmacological Mechanism and Clinical Trials." Frontiers in Oncology, vol. 13, 2023, https://doi.org/10.3389/fonc.2023.1133828.
